Table 2.

Anthropomorphic Characteristics and Supplemental Opioid Requirements

	All Analyses (n= 36)	Exclusively Intent- to-Treat Analyses (n = 9)	P-Value
Age (yr)	60 (9)	65 (9)	0.14
Sex (female / male)	21 / 15	7 / 2	0.45
Height (cm)	171 (11)	164 (10)	0.08
Weight (kg)	90 (19)	97 (21)	0.38
Body mass index (kg/m2)	30 (5)	36 (8)	0.08
Morphine equivalents, intraoperative (mg)	2 (2-2)	2 (1–2)	0.89
Morphine equivalents, recovery room (mg)	7 (5–14)	8 (1–11)	0.37
Morphine equivalents, postrecovery room through postoperative day 2 (mg)	42 (33–60)	28 (27–37)	0.04

Values are reported as number of subjects; mean (SD) for parametric data; or median (interquartile) for nonparametric data

Because this was a pharmacodynamics study—as opposed to an outcomes trial—we prospectively elected to exclude from the primary analyses subjects who did not provide assessments for the primary endpoint. However, all subjects with bilateral successfully inserted catheters/blocks were included in post-hoc intent-to-treat secondary analyses.